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Abstract 
Background 
Patellar tendinopathy (PT) is a major cause of morbidity in both high-level and recreational athletes. Whilst 
there is good evidence for the effectiveness of eccentric exercise regimens in its treatment, a large proportion 
of patients have disease which is refractory to such treatments. This has led to the development of novel 
techniques including platelet-rich plasma (PRP) injection, which aims to stimulate a normal healing response 
within the abnormal patellar tendon. However, little evidence exists at present to support its use. 
Purpose 
The aim of this systematic review was to determine the safety and effectiveness of PRP in the treatment of PT, 
and to quantify its effectiveness relative to other therapies for PT.  
Study design 
Systematic review. 
Methods 
A systematic review was conducted in accordance with the PRISMA guidelines. A literature review was 
conducted of the Medline, EMBASE and Cochrane databases, as well as trial registries. Both single-arm and 
comparative studies were included. The outcomes of interest were pain (as measured by visual-analogue or 
other, comparable scoring systems), functional scores and return to sport. Study quality and risk of bias were 
assessed using the MINORS score (for non-randomised studies) and the Cochrane risk of bias tool. 
Results 
Eleven studies fitted the inclusion criteria. Of these, two were randomised, controlled trials (RCTs), and one 
was a prospective, non-randomised cohort study. The remainder were single-arm case series. All non-
comparative studies demonstrated a significant improvement in pain and function following PRP injection. 
Complications and adverse outcomes were rare. The results of the comparative studies were inconsistent and 
superiority of PRP over control treatments could not be conclusively demonstrated. 
Conclusions 
PRP is a safe and promising therapy in the treatment of recalcitrant PT. However, its superiority over other 
treatments such as physiotherapy remains unproven. Further RCTs are required to determine the relative 
effectiveness of the many available treatments for PT, and to determine the subgroups of patients who stand 
to gain the most from the use of these therapies. 
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Introduction 
Patellar tendinopathy (PT, also known as Jumper’s Knee or Patellar Tendinitis) is a major cause of morbidity in 
both recreational and elite athletes, and is a leading factor contributing to the decision to retire from high-
level sport
32
. The prevalence of symptomatic PT in high-risk sports such as volleyball may be as high as 45%
23
. 
Ultrasound may reveal sub-clinical disease in a further proportion of asymptomatic athletes
6
. The mainstay of 
treatment is rest with physiotherapy in the form of eccentric exercises; corticosteroid injections and surgical 
debridement are reserved for recalcitrant cases
25
. In recent years, newer treatments such as ultrasound, extra-
corporeal shockwave therapy (ESWT) and novel injectables such as platelet-rich plasma (PRP) have become 
widespread
26
.  
Platelet-rich plasma (PRP) is a concentrate of platelets and growth factors produced by centrifugation from a 
sample of autologous blood. The use of PRP was popularised in the 1990s in plastic and maxillofacial surgery
28
, 
but its use has grown markedly in the field of orthopaedics in the last ten years (Error! Reference source not 
found.). Current applications of PRP in orthopaedics include the treatment of muscle or ligament injuries, 
tendinopathies and enthesiopathies, osteoarthritis, and as an adjunct to operative treatments
10
. The use of 
PRP is intended to enhance the native ability of tissues to repair themselves by the presence of high 
concentrations of growth factors
31
. Given that PT is believed to be a disorder of tendon repair, the use of PRP 
holds great promise in this context
25
. This is supported by the results of preclinical studies which have 
demonstrated increased levels of macrophages and Type I and III collagen in tendons treated with PRP
10
. 
However, whilst PRP has become increasingly widely-used for PT, high-quality randomised studies examining 
its use have only recently started reporting
5, 31
.  
The aim of this systematic review is to assess the state of the evidence for the use of PRP for the treatment of 
PT. Specifically, we aimed to determine the safety of PRP in the context of PT, the effect of PRP on knee pain, 
function, and return to sports, and the relative effectiveness of PRP compared to current gold-standard 
treatments for PT. 
Methods 
Systematic review was performed according to the PRISMA guidelines
24
. The review was registered 
prospectively in the PROSPERO International Prospective Register of Systematic Reviews (registration number 
CRD***********).  
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A search was conducted of studies contained within the Medline, EMBASE and Cochrane databases between 
1
st
 January 1974 and 13
th
 February 2014. The search terms were the same for each: “(patellar or patella) AND 
(platelet OR PRP)”. Inclusion criteria were: all studies examining the effect of platelet-rich plasma on adults 
with non-surgically treated patellar tendinopathy, published in English, Spanish or French, in the time-period 
of the search. Studies were excluded if a more recent report of the same cohort of patients were available, or 
if patients had undergone, or were undergoing surgery at the same time as receiving PRP. Studies examining 
multiple tendinopathies were excluded if data were not presented separately for PT.  Eligible studies included 
randomised controlled trials (RCTs), cohort or case-control studies, and case series. Case reports pertaining to 
complications are also reported. Titles of identified studies were screened to identify those related to the 
subject of interest; the abstracts of these studies were then screened and the full-text manuscripts of relevant 
studies were retrieved for inclusion in the review. Finally, three clinical trial databases (clinicaltrials.gov, the EU 
clinical trials register, and the ISRCTN register) were searched using the same search string to identify 
unreported trials or those that are in progress.  
Studies that met the inclusion criteria were read and data were extracted. The two authors extracted the data 
independently from each study using the same forms. For comparative studies, Forest plots were produced to 
visualise the outcome of multiple studies. Risk of bias in retrieved RCTs was assessed using the Cochrane 
Collaboration tool
14
; for non-randomised and non-comparative studies the Methodological Index for Non-
Randomised Studies (MINORS) was used
27
. Inadequate numbers of comparative studies were identified to 
justify meta-analysis; as a result, a descriptive systematic review was undertaken with no attempt at statistical 
data synthesis. 
Results 
Results of literature search 
The PubMed search returned 86 citations, and the EMBASE search returned an additional 138. The search of 
the Cochrane library revealed one systematic review (of PRP for any tendinopathy) which contained 19 
studies, of which one concerned PT. The protocol for screening and exclusion of studies is given in the flow-
chart in Error! Reference source not found.. Ultimately, 11 studies were included in the final review. Of the 11 
studies, three compared PRP to a control intervention (two randomised, controlled trials and one prospective 
cohort study)
5, 8, 31
. Of the remaining seven studies, one was a cohort study comparing two groups of patients 
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receiving PRP (the groups were defined on the basis of previous interventions and for the purposes of this 
review this study is treated as a case series)
12
; six were case series
3, 7, 9, 20, 34
; and one was a report of three 
cases
2
. Details of the included studies are given in Error! Reference source not found..  
Non-comparative studies 
This review contains eight non-comparative studies, with a combined total of 181 patients. All are consecutive 
case series, except for one cohort study comparing two groups of patients receiving PRP, and one report of 
three cases in which symptoms deteriorated after PRP treatment. 
The protocol for PRP use varies between studies, with 1-3 injections being given at varying intervals. Most use 
ultrasound to locate the point of maximal tendinopathy, but the studies of Gosens
12
, Filardo
9
 and Kon
20
 did not 
use ultrasound guidance and the study of Wilson
34
 does not specify. Similarly, the use of local anaesthetic (LA) 
varies, with one study (Gosens et al
12
) specifying that bupivacaine and adrenaline were injected with the PRP; 
all other studies specify that LA was not used, that it was only used subcuataneously, or did not specify (Error! 
Reference source not found.).  
Pain and functional outcomes and return to sport 
All of the case series report improvements in pain and functional outcomes at between six months and two 
years following PRP injection (Table 2), although to varying degrees. Four studies report on return to sport. 
Charrouset et al
3
 report that 75% of patients returned to their pre-injection activity by the three month mark, 
and that this was sustained to two years; similar findings were reported by Filardo et al (81% return to sport)
9
, 
and Kon et al reports that most patients were able to return to their pre-symptom level of sporting activity
20
. 
However, the study of Gosens et al reports that only 22% of their patients were able to exercise without pain 
at six months
12
.   
Adverse outcomes 
Three studies report on patients who were deemed to have failed treatment and who went on to surgery 
(total of 11 tendons). Bowman
2
 reports on three treatment failures where pain worsened following PRP 
injection with a commensurate change in USS/MRI findings. All improved following a prolonged period of 
physiotherapy (with ESWT in one patient). Ferrero et al
7
 report three cases of severe post-procedure pain, 
which they attribute to inflammatory response. Kon et al report one similar case
20
; in all four cases, symptoms 
resolved with conservative treatment. Several studies make the link between compliance with the 
rehabilitation regimen and ultimate success following injection. 
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Comparative studies 
Three studies compare PRP to control interventions. Of these, two are RCTs. Dragoo et al randomised 23 
patients with MRI-confirmed chronic PT to receive a single injection of PRP, dry-needlng and an exercise 
regimen (n=10) or dry needling and exercise alone (n=13)
5
. They report improvement in both groups, but a 
significantly superior VISA-P score for the PRP group at 12 weeks (improvement of 25.4 points ±23.3 in the PRP 
group, compared to 5.2 ±12.5 in controls, p=0.02). However, no difference is seen in terms of pain, and the 
effect on VISA-P was lost by six months. Lysholm score was significantly better in the control group than the 
PRP group at six months (improvement by 14.7 ±19.1 in the PRP group compared to 45.4 ±18.8 in the controls, 
p=0.006).  
Vetrano et al randomised 46 patients with USS-confirmed chronic PT to receive either two injections of PRP, 
two weeks apart, and an exercise programme (n=23), or three sessions of ESWT (over one week) with the 
same exercise programme
31
. They report improvement in both groups, but greater improvements in VISA-P 
score and pain in the PRP group at two, six and twelve months, and greater satisfaction in the PRP group. 
Neither this study nor the study of Dragoo et al
5
, report any clinically relevant side-effects in any patient. 
The third comparative study was the prospective cohort study of Filardo et al. 15 patients who had failed 
conservative (10 patients) or surgical (5 patients) treatment underwent three PRP injections, at 15-day 
intervals and a physiotherapy regimen
9
. The control group had not had any previous treatment; they received 
the physiotherapy regimen alone. The control group was comparable in terms of age and pre-operative 
symptoms, but had had symptoms for a significantly shorter period of time (mean of 8.4 months, compared to 
24.1 months in the PRP group, p=0.004). No significant differences were determined between the groups in 
either pain or VISA-P at six months following the intervention. The results of the comparative studies in terms 
of VISA-P and pain are given in Figures 3 and 4. 
Unpublished and ongoing studies 
Only one study was returned from the search of clinical trial registries. Trial number NCT01843504, registered 
on ClinicalTrials.gov, is a single-blind randomised trial of (n=44) comparing PRP to placebo in patients with 
established PT (for more than three months) refractory to physiotherapy and other non-surgical treatments. 
The PRP group will receive a single injection of 5mL PRP under ultrasound-guidance. The control group will 
receive the same volume of normal saline. It is listed as being in the recruitment phase with an estimated 
completion date of March 2014. In common with the other RCTs reported above, the primary outcome 
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measure is the VISA-P score, along with the IKDC score and an ultrasound assessment of the tendon. 
Outcomes will be reported at intervals up to 32 weeks post-injection. 
Methodological quality and bias assessment 
The two randomised trials were assessed using the Cochrane tool. This tool was developed as a qualitative 
measure and does not produce a score, but rather presents the assessed risk of bias in seven domains. Both 
trials presented a low risk of bias overall; results of the assessments are presented in Error! Reference source 
not found.. The non-comparative studies were assessed using the MINORS score. There was substantial 
variation in the methodological scores between studies. Most studies were reported to be prospective, and 
both choice of outcome measure and follow-up interval were appropriate in all studies. However, most studies 
failed to report whether the patients were recruited consecutively or whether the assessors were blinded, and 
four of the seven studies failed to report the level of loss to follow-up. 
Discussion 
This systematic review has identified a growing number of comparative and non-comparative studies assessing 
the effectiveness of PRP in the treatment of PT. Amongst those studies were two recent, high-quality RCTs. In 
the published literature, PRP appears to be safe, with few reports of complications associated with its use in 
PT. In case series of PRP for PT, statistically significant improvements have been demonstrated in both pain 
and functional scores, at follow-up intervals up to two years. However, the comparative studies have not 
demonstrated conclusively that PRP is superior to existing treatments, either in terms of pain or functional 
outcomes. 
The conclusions that can be drawn from this review are limited by the paucity of available, comparative, 
studies. Meaningful meta-analysis was not possible due to the small numbers of RCTs in this area and lack of 
standardisation of the interventions used in the control groups. However, the fact that there are two recent, 
high-quality randomised studies, with a third in progress, reflects the increasingly high standard of studies 
being published in the orthopaedic and sports medicine literature
4, 13
. Further encouragement can be drawn 
from the apparent consensus over outcome measures, with the VISA-P score (for function) and visual analogue 
pain scores being used in the majority of the included studies. PRP has been demonstrated to be safe and 
effective in the studies reported here; further appropriately-powered RCTs are required to demonstrate its 
superiority over existing treatments.  
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PT is believed to be a degenerative condition related to failure of the repair mechanisms of tendon. Repeated 
minor traumas overwhelm the tendon’s capacity to repair itself, and an area of abnormal tissue (tendinosis) 
develops, characterised by disorganisation of collagen fibres, calcification, proliferation of fibroblasts and 
neovascularisation, all of which are thought to be indicative of attempts at healing
29, 32
. As such, most novel 
therapies aim to disrupt the area of tendinosis and to allow ingress of interlukins and growth factors such as 
VEGF, stimulating the production of more ordered collagen bundles as part of a more normal healing 
response
21
. Such treatments include ESWT, low-intensity pulsed ultrasound, and injection therapies such as 
sclerosants, dry-needling and injections of autologous blood. PRP works by the same rationale, directly 
introducing these factors into the area of abnormal tendon, stimulating increased macrophage activity and 
resulting in increased levels of Type I and III collagen in vitro
10
.  
The theoretical effectiveness of each of these novel therapies is yet to be proven
11
. As is the case with PRP, the 
majority of studies examining each of these therapies are single-arm, retrospective case series
11
.  Like PRP, 
ESWT appears to be safe and single-arm studies report promising improvements in pain and function following 
its administration
30
. However, a single high-quality RCT (n=62) has been published which demonstrated no 
difference between athletes treated with active ESWT and those treated with placebo ESWT
35
. Low-intensity 
pulsed ultrasound has been demonstrated to accelerate healing of PT in animal models, but has not been 
demonstrated to be effective in clinical studies
11
. Injection therapies have shown promise, but there are few 
studies to support their widespread use. A series of 120 tendons treated with ultrasound-guided sclerosant 
therapy produced moderate improvements overall and a smaller RCT (n=43) by the same group demonstrated 
a statistically significant benefit of sclerosant therapy when compared to those receiving placebo injections of 
LA alone
15, 16
.  A single series of 44 patients receiving dry-needling and whole blood injection in addition to a 
structured rehabilitation programme has demonstrated a significant improvement in VISA-P scores at a mean 
of 14.8 months (range, 6-22 months)
17
. However, this study is limited by the lack of a control group. 
As such, the current mainstay of treatment for PT remains physiotherapy, with good evidence of effectiveness 
when programmes of eccentric training and decline squats are used
22, 25
. Various surgical treatments, both 
arthroscopic and open, have been described, and there is little evidence to suggest which is most effective
25
. 
Whilst there is a single RCT demonstrating superiority of arthroscopic patellar tendon shaving over sclerosant 
injection, a further RCT of 40 patients has demonstrated no advantage of open surgery over eccentric 
exercises alone
1, 33
. Studies of surgical management for PT are hampered by the difficulty with conducting 
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placebo-controlled trials in surgery, and by the fact that many other non-surgical treatments will generally 
have been attempted before surgery is offered.  
Even with access to the variety of therapies available, a complete cure for PT is rare: in one study of 991 male 
former elite athletes from a variety of sports, 20% reported that patellar tendinopathy was the main reason 
for retiring from elite sport, and many report mild ongoing symptoms following retirement
18, 19
.  
The results of this review raise the hope that PRP could be an effective treatment for PT. PRP has been 
demonstrated to be safe and effective in single-arm studies of patients with recalcitrant PT. However, there is 
currently insufficient evidence for the superiority of PRP over other treatments, and further high-quality 
randomised studies are required before PRP can be recommended as the gold-standard treatment for the 
large group of patients who suffer significant morbidity and activity restriction as a result of PT. 
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Legends for Figures and Tables 
 
Figures 
 
1. Number of publications per year featuring the term ‘Platelet-rich plasma’  
(figures taken from the PubMed database) 
 
10 
 
 
2. Flow chart of study protocol 
*review articles include narrative and systematic reviews of PRP in mixed populations but none 
examining PRP for patellar tendinopathy exclusively 
 
 
 
3. Forest plot – comparative studies of six month VISA-P 
 
 
 
4. Forest plot – comparative studies of six-month Visual Analogue Score for pain. 
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Tables 
1. Characteristics of included studies. RCT – Randomised Controlled Trial; MRI – magnetic resonance 
imaging; PT – patellar tendinopathy; PRP – platelet-rich plasma; VISA-P – Victoria Institute of Sport 
Assessment questionnaire (Patella); TAS – Tegner Activity Scale; VAS – Visual Analogue Scale; USS – 
Ultrasound Scan; ESWT – Extracorporeal Shock Wave Therapy; EQ-VAS – EuroQol general quality of 
life Visual Analogue Scale; IKDC – International Knee Documentation Committee score; SANE – Single 
Assessment Numeric Evaluation; Dx –diagnosis; ADLs – Activities of Daily Living; NSAIDs – Non-
Steroidal Anti-Inflammatory Drugs; SF-36 – Short Form (36) health survey. 
 
2. Outcomes of case series and methodological quality assessment (MINORS score) 
 
3.  Risk of bias assessment for the two randomised studies 
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Table 1 1 
1st author Year Design Prospective N  Inclusion criteria PRP protocol Comparator group Follow-up Outcome scores 
Charousset1 2014 Case series Yes 28 
USS / MRI –confirmed PT for ≥4 
months. Failed injections, ESWT, 
physiotherapy or laser therapy. 
PRP extracted with ACP kit (Arthrex). 3 x weekly 
injections under USS guidance. 1-2 extra injections 
given if clinically indicated. No LA used. 
Eccentric exercise programme. 
None 
4 weeks, 3, 6, 
12, 18 and 24 
months.  
VISA-P; Lysholm 
score; Pain VAS.MRI 
assessment of 
tendon. 
Dragoo2 2014 RCT Yes 23 
MRI-confirmed PT refractory to 6 
weeks physiotherapy. 
No previous surgery 
PRP extracted with GPSIII kit (Biomet). LA only 
subcutaneously. 10x needle penetration of sheath.  
PRP group received 6mL leukocyte-rich PRP.  
Eccentric exercise programme (both groups). 
Dry needling x 10; 
same eccentric 
exercise programme as 
PRP group 
3, 6, 9, 12 
weeks and ≥6 
months 
VISA-P; TAS;  
Lysholm score;  
Pain VAS; SF-12 
Vetrano3 2013 RCT Yes 46 
USS-confirmed PT for ≥6 months. 
Elite/non-elite athletes. Unilateral. 
No previous surgery or steroids. 
PRP extracted with Recover kit (Kaylight). 
2 x 2mL PRP in 2 weeks at hypoechogenic portion of 
tendon under USS guidance. No LA used. 
Eccentric exercises (2 week course, both groups). 
ESWT; 3 sessions at 
48-72hr intervals. 2,400 
impulses; EFD 0.17-
0.25mJ/mm2. 
2, 6, and 12 
months 
VISA-P; Pain VAS; 
modified Blazina 
scale 
Filardo4 2013 Case series Yes 43 
MRI / USS-confirmed PT for ≥3 
months. Failed injections, ESWT, or 
surgical management 
3 sessions of PRP at fortnightly intervals.  
In each, multiple injections into USS-identified site 
Eccentric exercise programme (12 weeks).  
LA not specified 
None 
2 and 6 months 
and ‘latest’, min 
36 months, 
(mean 48.6) 
VISA-P, TAS, EQ-
VAS, Blazina scale, 
satisfaction, return to 
sports. USS in 26 pts 
Bowman5 2013 Case reports - - - - - - - 
Wilson6 2012 Case series Yes 8 
USS-confirmed chronic PT. Failed 
conservative therapy for ≥12 months 
Unspecified None 48 weeks 
IKDC,  
Knee SANE,  
USS-measured 
tendon thickness 
Gosens7 2012 Cohort Yes 36 
Chronic PT refractory to physiotherapy 
(clinical Dx; MRI in 21). Group 1 (n=14) 
previous injections / surgery. Group 2 
(n=22) no previous injections / surgery. 
PRP extracted with Recover kit (Biomet). 3mL PRP 
with bupivacaine/adrenaline. 1mL injected into point of 
maximal tenderness. Remainder injected into tendon / 
patella junction (5 penetrations). Eccentric exercises. 
Comparison on basis of 
previous treatment. All 
patients received PRP 
Latest follow-up, 
mean 18.4 
months. 
VISA-P, VAS (x 3) for 
pain during ADLs, 
work, and sport. 
Ferrero8 2012 Case Series Yes 28 
MRI / USS-confirmed PT for ≥3 
months. Failed ESWT, US therapy or 
corticosteroid injection. No systemic 
disease or recent NSAIDs. 
2 sessions, three weeks apart.  
In each, dry needling then injection of PRP into 
degenerate area of tendon under USS-guidance. 
LA only used subcutaneously. 
None 
20 days and six 
months. 
VISA-P, USS-
measured tendon 
thickness. 
Filardo9 2010 Cohort Yes 31 
MRI / USS-confirmed PT for >3 
months. PRP group: failed injections / 
surgery. Controls: no prior treatment. 
No systemic disease / recent NSAIDs. 
3 sessions, each 15 days apart. Non USS-guided 
multiple injections into tender area (4-6 penetrations). 
24 hours of rest with cryotherapy then one month 
strengthening programme. LA not specified.   
Physiotherapy – same 
regimen as PRP group. 
Six months 
TAS, EQ-VAS,  
Pain VAS. 
Kon9 2009 Case series Yes 27 
MRI / USS-confirmed PT for >3 
months. Failed injections / surgery. 
3 sessions, each 15 days apart. Non USS-guided 
multiple injections into tender area (4-6 penetrations). 
24 hours of rest with cryotherapy then one month 
strengthening programme. LA not specified.  
None Six months 
TAS, EQ-VAS, SF-
36. Patient-reported 
functional recovery 
and satisfaction. 
Volpi10 2007 Case series No 10 
MRI – confirmed Chronic PT <1 year 
history. Failed physiotherapy, NSAIDs, 
ESWT. 
PRP extracted with GPSII kit (Biomet). Subcutaneous 
LA only. USS-guided injection (5-8 penetrations). 
Eccentric exercises from 5 weeks.  
None 
Latest follow-up, 
mean 120 days. 
VISA-P 
MRI appearences 
 2 
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Table 2 3 
Study 
MINORS 
score 
(out of 14) 
Principal 
follow-up 
interval 
N  
Primary pain outcome Primary functional outcome Other outcomes 
Score used Baseline Follow-up P Value Score used Baseline Follow-up P value Outcome Baseline Follow-up P Value 
Charousset  
2014 
12 2 years 28 VAS 7 (4-8) 0.8 (0-3) <0.001 VISA-P 39 (28-60) 94 (60-100) <0.001 Lysholm 60 (40-70) 
96 (70-
100) 
<0.001 
Filardo  
2013 
8 6 months 43 Blazina 
3a (16 pts) 
3b (27 pts) 
0-2 (32 pts) 
3a-b (11 pts) 
<0.001 VISA-P 44.1 ±15.6 76.6 ± 25 <0.001 
Quality of life 
(EQ-VAS) 
67.8 ±14.7 83.5 ±15.2 <0.001 
Wilson  
2012 
10 48 weeks  8 - - - - IKDC 52.3 ±8.6 83.0 ±11.1 0.01 
USS tendon 
thickness (mm) 
10.4 ±1.8 9.1 ±0.9 0.02 
Gosens  
2012 
7 
18.4 
months 
(mean) 
14 (gp 1) VAS (during 
sport) 
8.6 ±0.9  3.8 ±2.9 0.003 
VISA-P 
41.8 ±14.3 56.3 ±26.2 0.093 VAS (during 
ADLs) 
6.5 ±2.3 2.8 ±2.2 0.005 
22 (gp 2) 8.5 ±1.1 5.1 ±3.2 <0.001 39.1 ±16.6 58.6 ±25.4 0.003 5.6 ±2.9 2.6 ±27 0.001 
Ferrero  
2012 
7 6 months 28 - - - - VISA-P 56 ±18 74 ±14 0.044 
USS tendon 
thickness (mm) 
17 ±8 11 ±5 0.031 
Kon  
2009 
10 6 months 27 SF-36 pain 35.7  71.6 <0.001 - - - - Satisfaction - 80% - 
Volpi  
2007 
5 
120 days 
(mean) 
11 - - - - VISA-P 39.3 (24-64) 75.0 (58-92) <0.001 MRI    
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Table 3 6 
 7 
Study 
MINORS 
score 
(out of 14) 
Principal 
follow-up 
interval 
N  
Primary pain outcome Primary functional outcome Other outcomes 
Score used Baseline Follow-up P Value Score used Baseline Follow-up P value Outcome Baseline Follow-up P Value 
Charousset  
2014 
12 2 years 28 VAS 7 (4-8) 0.8 (0-3) <0.001 VISA-P 39 (28-60) 94 (60-100) <0.001 Lysholm 60 (40-70) 
96 (70-
100) 
<0.001 
Filardo  
2013 
8 6 months 43 Blazina 
3a (16 pts) 
3b (27 pts) 
0-2 (32 pts) 
3a-b (11 pts) 
<0.001 VISA-P 44.1 ±15.6 76.6 ± 25 <0.001 
Quality of life 
(EQ-VAS) 
67.8 ±14.7 83.5 ±15.2 <0.001 
Wilson  
2012 
10 48 weeks  8 - - - - IKDC 52.3 ±8.6 83.0 ±11.1 0.01 
USS tendon 
thickness (mm) 
10.4 ±1.8 9.1 ±0.9 0.02 
Gosens  
2012 
7 
18.4 
months 
(mean) 
14 (gp 1) VAS (during 
sport) 
8.6 ±0.9  3.8 ±2.9 0.003 
VISA-P 
41.8 ±14.3 56.3 ±26.2 0.093 VAS (during 
ADLs) 
6.5 ±2.3 2.8 ±2.2 0.005 
22 (gp 2) 8.5 ±1.1 5.1 ±3.2 <0.001 39.1 ±16.6 58.6 ±25.4 0.003 5.6 ±2.9 2.6 ±27 0.001 
Ferrero  
2012 
7 6 months 28 - - - - VISA-P 56 ±18 74 ±14 0.044 
USS tendon 
thickness (mm) 
17 ±8 11 ±5 0.031 
Kon  
2009 
10 6 months 27 SF-36 pain 35.7  71.6 <0.001 - - - - Satisfaction - 80% - 
Volpi  
2007 
5 
120 days 
(mean) 
11 - - - - VISA-P 39.3 (24-64) 75.0 (58-92) <0.001 MRI    
15 
 
References 8 
1. Bahr R, Fossan B, Loken S, Engebretsen L. Surgical treatment compared with eccentric training for 9 
patellar tendinopathy (Jumper's Knee). A randomized, controlled trial. J Bone Joint Surg Am. 10 
2006;88(8):1689-1698. 11 
2. Bowman KF, Jr., Muller B, Middleton K, Fink C, Harner CD, Fu FH. Progression of patellar tendinitis 12 
following treatment with platelet-rich plasma: case reports. Knee Surg Sports Traumatol Arthrosc. 13 
2013;21(9):2035-2039. 14 
3. Charousset C, Zaoui A, Bellaiche L, Bouyer B. Are Multiple Platelet-Rich Plasma Injections Useful for 15 
Treatment of Chronic Patellar Tendinopathy in Athletes?: A Prospective Study. Am J Sports Med. 16 
2014;42(4):906-11. 17 
4. Cvetanovich GL, Fillingham YA, Harris JD, Erickson BJ, Verma NN, Bach BR, Jr. Publication and Level of 18 
Evidence Trends in The American Journal of Sports Medicine From 1996 to 2011. Am J Sports Med. 19 
2014 (published online ahead of print). 20 
5. Dragoo JL, Wasterlain AS, Braun HJ, Nead KT. Platelet-Rich Plasma as a Treatment for Patellar 21 
Tendinopathy: A Double-Blind, Randomized Controlled Trial. Am J Sports Med. 2014;42(3):610-8. 22 
6. Durcan L, Coole A, McCarthy E, et al. The prevalence of patellar tendinopathy in elite academy rugby: 23 
A clinical and imaging study. J Sci Med Sport. 2014;17(2):173-6. 24 
7. Ferrero G, Fabbro E, Orlandi D, et al. Ultrasound-guided injection of platelet-rich plasma in chronic 25 
Achilles and patellar tendinopathy. J Ultrasound. 2012;15(4):260-266. 26 
8. Filardo G, Kon E, Della Villa S, Vincentelli F, Fornasari PM, Marcacci M. Use of platelet-rich plasma for 27 
the treatment of refractory jumper's knee. Int Orthop. 2010;34(6):909-915. 28 
9. Filardo G, Kon E, Di Matteo B, Pelotti P, Di Martino A, Marcacci M. Platelet-rich plasma for the 29 
treatment of patellar tendinopathy: clinical and imaging findings at medium-term follow-up. Int 30 
Orthop. 2013;37(8):1583-1589. 31 
10. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic 32 
science to clinical applications. Am J Sports Med. 2009;37(11):2259-2272. 33 
11. Gaida JE, Cook J. Treatment options for patellar tendinopathy: critical review. Curr Sports Med Rep. 34 
2011;10(5):255-270. 35 
12. Gosens T, Den Oudsten BL, Fievez E, van 't Spijker P, Fievez A. Pain and activity levels before and after 36 
platelet-rich plasma injection treatment of patellar tendinopathy: a prospective cohort study and the 37 
influence of previous treatments. Int Orthop. 2012;36(9):1941-1946. 38 
13. Hanzlik S, Mahabir RC, Baynosa RC, Khiabani KT. Levels of evidence in research published in The 39 
Journal of Bone and Joint Surgery (American Volume) over the last thirty years. J Bone Joint Surg Am. 40 
2009;91(2):425-428. 41 
14. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias 42 
in randomised trials. BMJ. 2011;343:d5928. 43 
15. Hoksrud A, Ohberg L, Alfredson H, Bahr R. Ultrasound-guided sclerosis of neovessels in painful chronic 44 
patellar tendinopathy: a randomized controlled trial. Am J Sports Med. 2006;34(11):1738-1746. 45 
16. Hoksrud A, Torgalsen T, Harstad H, et al. Ultrasound-guided sclerosis of neovessels in patellar 46 
tendinopathy: a prospective study of 101 patients. Am J Sports Med. 2012;40(3):542-547. 47 
17. James SL, Ali K, Pocock C, et al. Ultrasound guided dry needling and autologous blood injection for 48 
patellar tendinosis. Br J Sports Med. 2007;41(8):518-521. 49 
18. Kettunen JA, Kujala UM, Kaprio J, Koskenvuo M, Sarna S. Lower-limb function among former elite 50 
male athletes. Am J Sports Med. 2001;29(1):2-8. 51 
19. Kettunen JA, Kvist M, Alanen E, Kujala UM. Long-term prognosis for jumper's knee in male athletes. A 52 
prospective follow-up study. Am J Sports Med. 2002;30(5):689-692. 53 
20. Kon E, Filardo G, Delcogliano M, et al. Platelet-rich plasma: new clinical application: a pilot study for 54 
treatment of jumper's knee. Injury. 2009;40(6):598-603. 55 
21. Lane JG, Healey RM, Chase DC, Amiel D. Use of platelet-rich plasma to enhance tendon function and 56 
cellularity. Am J Orthop (Belle Mead NJ). 2013;42(5):209-214. 57 
22. Larsson ME, Kall I, Nilsson-Helander K. Treatment of patellar tendinopathy--a systematic review of 58 
randomized controlled trials. Knee Surg Sports Traumatol Arthrosc. 2012;20(8):1632-1646. 59 
23. Lian OB, Engebretsen L, Bahr R. Prevalence of jumper's knee among elite athletes from different 60 
sports: a cross-sectional study. Am J Sports Med. 2005;33(4):561-567. 61 
16 
 
24. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews 62 
and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. 63 
25. Rodriguez-Merchan EC. The treatment of patellar tendinopathy. J Orthop Traumatol. 2013;14(2):77-64 
81. 65 
26. Scott A, Docking S, Vicenzino B, et al. Sports and exercise-related tendinopathies: a review of selected 66 
topical issues by participants of the second International Scientific Tendinopathy Symposium (ISTS) 67 
Vancouver 2012. Br J Sports Med. 2013;47(9):536-544. 68 
27. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-69 
randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 70 
2003;73(9):712-716. 71 
28. Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. A systematic review of the use of platelet-rich 72 
plasma in sports medicine as a new treatment for tendon and ligament injuries. Clin J Sport Med. 73 
2011;21(4):344-352. 74 
29. van Ark M, Zwerver J, van den Akker-Scheek I. Injection treatments for patellar tendinopathy. Br J 75 
Sports Med. 2011;45(13):1068-1076. 76 
30. van Leeuwen MT, Zwerver J, van den Akker-Scheek I. Extracorporeal shockwave therapy for patellar 77 
tendinopathy: a review of the literature. Br J Sports Med. 2009;43(3):163-168. 78 
31. Vetrano M, Castorina A, Vulpiani MC, Baldini R, Pavan A, Ferretti A. Platelet-rich plasma versus 79 
focused shock waves in the treatment of jumper's knee in athletes. Am J Sports Med. 2013;41(4):795-80 
803. 81 
32. Warden SJ, Brukner P. Patellar tendinopathy. Clin Sports Med. 2003;22(4):743-759. 82 
33. Willberg L, Sunding K, Forssblad M, Fahlstrom M, Alfredson H. Sclerosing polidocanol injections or 83 
arthroscopic shaving to treat patellar tendinopathy/jumper's knee? A randomised controlled study. Br 84 
J Sports Med. 2011;45(5):411-415. 85 
34. Wilson JJ, Lee KS, Almasi SJ, Baer GS, Johnson GB, Dubin E. Platelet-rich plasma for the treatment of 86 
chronic patellar tendinopathy: Clinical and radiographic outcomes. Clinical Journal of Sport Medicine. 87 
2012;22 (2):190. 88 
35. Zwerver J, Hartgens F, Verhagen E, van der Worp H, van den Akker-Scheek I, Diercks RL. No effect of 89 
extracorporeal shockwave therapy on patellar tendinopathy in jumping athletes during the 90 
competitive season: a randomized clinical trial. Am J Sports Med. 2011;39(6):1191-1199. 91 
 92 
 93 
 94 
